AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02659293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: * Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~* Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~* Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16
Study NCT02659293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: * Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~* Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22
Study NCT01998607 — intervention group
Intervention type: OTHER
Intervention: Physician Survey
Description: Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
Study NCT02659293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide (Control)
Description: * Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~* Cycles 5 and beyond: best tolerated dose days 1-28
Study NCT03269669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scans
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT scans
Study NCT03269669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03269669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03269669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT03269669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT03269669 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Given IV
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scans
Study NCT02724033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional nerve block
Description: regional nerve block
Study NCT02724033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiemetic
Description: Antiemetic
Study NCT01093495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP
Study NCT01093495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Cannula
Description: Nasal Cannula
Study NCT03615092 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Root coverage with extended flap technique and acelular dermal matrix
Description: At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
Study NCT03615092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage with extended flap technique and acelular dermal matrix
Description: At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
Study NCT01671410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral morphine
Description: Oral morphine for the treatment of neonatal abstinence syndrome
Study NCT01671410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine
Description: Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
Study NCT05527925 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Brain testing of patients using MRI
Study NCT04234438 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)
Description: Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
Study NCT03317587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INSPIRE
Description: Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
Study NCT00257127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 7-valent conjugate vaccine
Description: 0.5 mL administered intramuscularly
Study NCT00257127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Description: 0.5 mL administered intramuscularly
Study NCT00257127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: 0.5 mL administered intramuscularly
Study NCT03269669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scans
Study NCT03269669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT03269669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Given PO
Study NCT00257127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella virus vaccine, live
Description: 0.5 mL administered subcutaneously
Study NCT00427414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal daunorubicin citrate
Description: 40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
Study NCT01179295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766
Description: BAY86-9766 30 mg twice a day (bid).
Study NCT01179295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766
Description: BAY86-9766 50 mg twice a day (bid).
Study NCT01179295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766
Description: BAY86-9766 100 mg once a day (od)
Study NCT01179295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766
Description: BAY86-9766 60 mg once a day (od)
Study NCT00290472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Study NCT02488278 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: GlucoMe Glucose Monitoring Device
Description: Perform a blood glucose test using the application and device
Study NCT03175523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: quantitative coronary angiography guided Bioresorbable scaffold implantation
Description: In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
Study NCT03175523 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imaging guided Bioresorbable scaffold implantation
Description: In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
Study NCT04146558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized internal ayurvedic treatment
Description: All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration
Study NCT04146558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External ayurvedic treatment
Description: Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
Study NCT00997074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
Study NCT04408456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCQ
Description: Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
Study NCT04408456 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy
Description: Home quarantine for 2 weeks plus social distancing plus personal hygiene
Study NCT04408456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Home quarantine for 2 weeks plus social distancing plus personal hygiene
Study NCT03269669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03242213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile App
Description: The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
Study NCT02607527 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mitral Valve IRIS Ring
Description: Transcatheter implantation of the IRIS
Study NCT03342157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: senna/docusate
Description: Stimulant laxative
Study NCT02887339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Website
Description: Additional training website can be found at gtextraing.org
Study NCT02887339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Standard training given by OPOs and GTEx staff
Study NCT03428386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric plication ileal bypass
Description: laparoscopic plication of the greater curvature of the stomach then the duodeno-jejunal junction is identified and 300 cm is measured downwards. The selected loop will be ascended without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just 3 cm away from the pylorus with a linear stapler charged with a green cartridge, the diameter of ileal antrum anastomosis is not exceeding 3 cm in diameter. The staple defect is closed with a two-layer running 3/0 polyglactin suture
Study NCT03672318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR138 T Cells
Description: The MTD is defined as the dose at which approximately 0.20 of subjects experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10\^6 cells/m\^2 Dose level 2: 1X10\^7 cells/m\^2 Dose level 3: 2.5X10\^7 cells/m\^2 Dose level 4: 5X10\^7 cells/m\^2 Dose level 5: 1x10\^8 cells/m\^2 Dose level 6: 2x10\^8 cells/m\^2~Six subjects will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m\^2 and fludarabine 30 mg/m\^2 given once daily for three days.
Study NCT03511365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic Formulation VSL#3
Description: Probiotic VSL#3 administration.
Study NCT01023282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR325
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
Study NCT01023282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACR325
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
Study NCT01023282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
Study NCT00803556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvespimycin
Description: Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
Study NCT00803556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
Study NCT00803556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
Study NCT01627145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Solifenacin 5 mg qd,
Study NCT00900796 — intervention group
Intervention type: OTHER
Intervention: Treatment switching
Description: If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
Study NCT01617044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
Study NCT01617044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02688413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindMotionPRO
Description: The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
Study NCT02688413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed Prescribed Exercises
Description: GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
Study NCT04452643 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BACMUNE (MV130)
Description: BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
Study NCT04452643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a solution on sodium chloride at 0.9%
Study NCT03698734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evening primrose oil(EPO)
Description: primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol
Study NCT03698734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
Study NCT05252689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monolithic zirconia single posterior crowns with deep chamfer finish line
Description: deep chamfer of 1 mm average thickness for cervical finish line, a convergence angle of 6-12° on each side and up to 20° total, in some studies, is acceptable and occlusal reduction of 1,5-2 mm
Study NCT05252689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monolithic zirconia single posterior crowns with vertical finish line
Description: using special round-ended 2 degrees tapered diamond burs a non-working tip (batt bur). It has coronal diameter of 1.2 mm, apical diameter of 0.7 mm, and non- cutting end of 1 mm, which reduces or avoids damage to the connective attachment and allows a tooth-guided preparation procedure
Study NCT03947541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracolumbosacral (TLSO) brace
Description: Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.
Study NCT03947541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Bracing
Description: Participants will not wear a brace in the study.
Study NCT03094130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin
Study NCT03094130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study NCT03741361 — intervention group
Intervention type: OTHER
Intervention: anxiety and depression
Description: Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
Study NCT01713634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preflight
Description: 4-d controlled diet sessions will occur twice before flight.
Study NCT01713634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-flight
Description: 4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
Study NCT01839474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
Study NCT02939521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT02852226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre Exposure Prophylaxis
Description: Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.